A Quote, Financials, Valuation and Earnings

Bio-Rad Laboratories has a net margin of 20.64% compared to Agilent Technologies's net margin of -339.17%. Agilent Technologies's return on equity of 21.45% beat Bio-Rad Laboratories's return on equity of -9.62%.

Agilent Technologies has a consensus price target of $148.76, signalling upside risk potential of 10.52%. On the other hand Bio-Rad Laboratories has an analysts' consensus of -- which suggests that it could grow by 23.14%. Given that Bio-Rad Laboratories has higher upside potential than Agilent Technologies, analysts believe Bio-Rad Laboratories is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.066, which suggesting that the stock is 6.613% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.429%.

Agilent Technologies has a quarterly dividend of $0.24 per share corresponding to a yield of 0.7%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Bio-Rad Laboratories quarterly revenues of $649.7M. Agilent Technologies's net income of $351M is lower than Bio-Rad Laboratories's net income of $653.2M. Notably, Agilent Technologies's price-to-earnings ratio is 30.45x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.01x versus 3.62x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of 20.64% compared to Agilent Technologies's net margin of -728.57%. Agilent Technologies's return on equity of 21.45% beat Bionano Genomics's return on equity of -158.95%.

Agilent Technologies has a consensus price target of $148.76, signalling upside risk potential of 10.52%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 395.79%. Given that Bionano Genomics has higher upside potential than Agilent Technologies, analysts believe Bionano Genomics is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.066, which suggesting that the stock is 6.613% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.944%.

Agilent Technologies has a quarterly dividend of $0.24 per share corresponding to a yield of 0.7%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Bionano Genomics quarterly revenues of $6.1M. Agilent Technologies's net income of $351M is higher than Bionano Genomics's net income of -$44.2M. Notably, Agilent Technologies's price-to-earnings ratio is 30.45x while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.01x versus 0.28x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 20.64% compared to Agilent Technologies's net margin of 4.73%. Agilent Technologies's return on equity of 21.45% beat Bruker's return on equity of 19.61%.

Agilent Technologies has a consensus price target of $148.76, signalling upside risk potential of 10.52%. On the other hand Bruker has an analysts' consensus of $74.01 which suggests that it could grow by 28.96%. Given that Bruker has higher upside potential than Agilent Technologies, analysts believe Bruker is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.066, which suggesting that the stock is 6.613% more volatile than S&P 500. In comparison Bruker has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.733%.

Agilent Technologies has a quarterly dividend of $0.24 per share corresponding to a yield of 0.7%. Bruker offers a yield of 0.35% to investors and pays a quarterly dividend of $0.05 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Bruker quarterly revenues of $864.4M. Agilent Technologies's net income of $351M is higher than Bruker's net income of $40.9M. Notably, Agilent Technologies's price-to-earnings ratio is 30.45x while Bruker's PE ratio is 27.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.01x versus 2.62x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 20.64% compared to Agilent Technologies's net margin of -21.86%. Agilent Technologies's return on equity of 21.45% beat Harvard Bioscience's return on equity of -20.42%.

Agilent Technologies has a consensus price target of $148.76, signalling upside risk potential of 10.52%. On the other hand Harvard Bioscience has an analysts' consensus of -- which suggests that it could grow by 197.62%. Given that Harvard Bioscience has higher upside potential than Agilent Technologies, analysts believe Harvard Bioscience is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.066, which suggesting that the stock is 6.613% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.272, suggesting its more volatile than the S&P 500 by 27.217%.

Agilent Technologies has a quarterly dividend of $0.24 per share corresponding to a yield of 0.7%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Harvard Bioscience quarterly revenues of $22M. Agilent Technologies's net income of $351M is higher than Harvard Bioscience's net income of -$4.8M. Notably, Agilent Technologies's price-to-earnings ratio is 30.45x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.01x versus 0.93x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.